Key result
Higher plasma 1-methylhistidine levels (4th vs. 1st quartile) were associated with an increased risk of acute myocardial infarction.
Why the study?
Are elevated plasma levels of 1- and 3-methylhistidine associated with an increased risk of acute myocardial infarction and mortality in patients with suspected chronic coronary syndrome?
Cohort (n=4,131)
Are elevated plasma levels of 1- and 3-methylhistidine associated with an increased risk of acute myocardial infarction and mortality in patients with suspected chronic coronary syndrome?
Answers are grounded in this paper and cite their sources.
Elevated plasma 1-methylhistidine levels, a biomarker of dietary meat intake, are associated with a significantly increased long-term risk of acute myocardial infarction and mortality in patients with suspected chronic coronary syndrome.
Background Elevated levels of 1- and 3-methylhistidine (MH) are indicative of higher dietary meat intake, whereas 3-MH also reflects muscle catabolism. Both biomarkers have been linked to oxidative stress and cardiometabolic risk factors; however, their associations with cardiovascular outcomes and survival are unknown. Purpose To investigate prospective associations of plasma 1- and 3-MH with long-term risk of acute myocardial infarction (AMI), all-cause mortality, and cardiovascular mortality. Methods Using Cox regression analysis, risk-associations were examined among 4131 subjects undergoing coronary angiography for suspected chronic coronary syndrome. Outcome data were obtained from national health registries. Results Median levels of 1- and 3-MH were 3.9 and 2.8 µmol/L, respectively. Median follow-up was 7.4 years for AMI and 10.3 years for mortality. During follow-up, 12.9% experienced an AMI, whereas 21.9% died. After multivariable adjustments for established cardiovascular risk factors and indices of renal function, the HR (95% CI) for AMI comparing the 4th vs. 1st 1-MH quartile were 1.45 (1.10-1.91, p=0.009). Corresponding HRs for all-cause mortality and cardiovascular mortality were 1.55 (1.24-1.93, p<0.001) and 1.56 (1.11-2.17, p=0.009), respectively. Additional adjustments for energy-adjusted protein intake resulted in only a minor attenuation of the estimates. For 3-MH, no significant associations were observed: HRs (95% CI) comparing the 4th vs. 1st 3-MH quartile were 1.13 (0.89-1.45, p=0.31) for AMI, 0.96 (0.79-1.17, p=0.69) for all-cause mortality, and 0.95 (0.71-1.26, p=0.71) for cardiovascular mortality. Conclusion In this large cohort of patients with suspected chronic coronary syndrome, higher plasma 1-MH levels were associated with an increased risk of future AMI and 10-year all-cause and cardiovascular mortality. In contrast, 3-MH had no prognostic value.
No takes yet. Share an insight, caveat, or question.
Bjornestad et al. (2025) conducted a cohort in suspected chronic coronary syndrome (n=4,131). Plasma 1-methylhistidine (1-MH) levels vs. 1st quartile of 1-MH was evaluated on acute myocardial infarction (AMI) (HR 1.45, 95% CI 1.10-1.91, p=0.009). Higher plasma 1-methylhistidine levels (4th vs. 1st quartile) were associated with an increased risk of acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: